Tate & Lyle agrees £2.7bn sale
Tate & Lyle (TATE) is set to be the latest large UK company to delist from the London market after agreeing to a £2.7bn takeover by US specialty ingredients group Ingredion (NYSE: INGR). The share price moved 13 per cent higher in morning trading as the market digested the terms of the deal.
Under the scheme of arrangement, Tate & Lyle shareholders will receive 595p per share in cash, plus permitted dividends of up to 20p per share, taking the headline value to 615p per share. The cash element a premium of around 59 per cent to the share price on 13 May when bid talks were first confirmed.
The Tate & Lyle board has unanimously recommended the offer, citing the certainty of cash against the risks in executing the company’s current strategy. Indeed, the backdrop to the deal was rather muted in certain respects - the board acknowledged that the 2026 financial year, which saw both revenue and pro forma adjusted Ebitda fall 3 per cent, was “disappointing”, along with uncertainty over the timing of a recovery.
So far, irrevocable undertakings to vote in favour of the scheme total 17.1 per cent of Tate & Lyle’s shares, including a 16.8 per cent stake held by Huber Equity Corporation.
The acquisition is expected to complete in the second half of 2027, subject to antitrust clearances across multiple jurisdictions.




